drugset / Trial / NCT02648282
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
Phase 2
Completed
58 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will be looking at whether combining cyclophosphamide, pembrolizumab (an antibody that blocks negative signals to T cells), GVAX (pancreatic cancer vaccine), and SBRT (focused radiation) is effective (anti-tumor activity) and safe in patients with locally advanced pancreatic cancer.
Timeline
- Start
- 2016-07-18
- Primary completion
- 2022-06-01
- Completion
- 2022-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GVAX pancreatic cancer vaccine | Vaccine | 5e+08 cells | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 200 mg/m2 | Intravenous |